

DAFTAR PUSTAKA

- Armbruster, N., Jasny, E., & Petsch, B. 2019, Advances in rna vaccines for preventive indications: A case study of a vaccine against rabies, *Vaccines*, **7**:4.
- Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A. (Mick), Watson, M., Zaks, T., & Ciaramella, G. 2017, Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. *Molecular Therapy*, **25**:1316–1327
- Blackburn, L. 2018, Policy Briefing - RNA vaccines: an introduction. University Of Cambridge.
- Bradley, E. S., & McNeil, D. G. 2017, *RNA Vaccines: Cancer Therapeutic Targets*, Springer Protocols, New York
- Carrigg, C., Rice, O., Kavanagh, S., Collins, G., & O'Flaherty, V. 2007, DNA extraction method affects microbial community profiles from soils and sediment, *Applied Microbiology and Biotechnology*, **77**:955–964.
- Cordeiro, A. S., & Alonso, M. J. 2016, Recent advances in vaccine delivery. *Pharmaceutical Patent Analyst*, **5**:49–73.
- Cristina Poveda, Biter, A. B., Bottazzi, M. E., & Strych, U. 2019, Establishing preferred product characterization for the evaluation of rna vaccine antigens. *Vaccines*, **7**:1–14
- Cohen, N. D., & Bordin, A. I. 2016, Principles of Vaccination, *Equine Clinical Immunology*, 263–278.
- Costello, L. (2019). The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety, *HHS Public Access Physiology & Behavior*, **176**:139–148.
- Démoulin, T., Ebensen, T., Schulze, K., Englezou, P. C., Pelliccia, M., Guzmán, C. A., Ruggli, N., & McCullough, K. C. 2017, Self-replicating RNA vaccine

- functionality modulated by fine-tuning of polyplex delivery vehicle structure. *Journal of Controlled Release*, **266**:256–271.
- Faghfuri, E., Pourfarzi, F., Faghfouri, A. H., Abdoli Shadbad, M., Hajiasgharzadeh, K., & Baradaran, B. 2020, Recent developments of RNA-based vaccines in cancer immunotherapy. *Expert Opinion on Biological Therapy*.
- Fuller, D. H., Ph, D., Berglund, P., & Ph, D. 2020, Amplifying RNA Vaccine Development, *Medicine*, 2469–2471.
- Hsin, J. P., & Manley, J. L. 2012, The RNA polymerase II CTD coordinates transcription and RNA processing. *Genes and Development*, **26**:2119–2137.
- Jahanafrooz, Z., Baradaran, B., Mosafer, J., Hashemzaei, M., Rezaei, T., Mokhtarzadeh, A., & Hamblin, M. R. 2020, Comparison of DNA and mRNA vaccines against cancer, *Elsevier Drug Discovery Today*, **25**:552–560.
- Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. 2020, The promise of mRNA vaccines: a biotech and industrial perspective. *Npj Vaccines*, **5**:3–8.
- Jin, J., Tarrant, R. D., Bolam, E. J., Angell-Manning, P., Soegaard, M., Pattinson, D. J., Dulal, P., Silk, S. E., Marshall, J. M., Dabbs, R. A., Nugent, F. L., Barrett, J. R., Hjerrild, K. A., Poulsen, L., Jørgensen, T., Brenner, T., Baleanu, I. N., Parracho, H. M., Tahiri-Alaoui, A., ... Draper, S. J. 2018, Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells. *Npj Vaccines*, **3**:1-12
- Kramps, T., & Elbers, K. 2017, Introduction to RNA vaccines, *Springer Protocols*, **1449**:1-11
- Lahariya, C. 2016, Vaccine epidemiology: A review. *Journal of Family Medicine and Primary Care*, **5**:7.
- Liu, M. A. 2014, A Comparison of Plasmid DNA and mRNA as Vaccine Technologies, *Vaccines & Vaccine Technologies*.

- McNamara, M. A., Nair, S. K., & Holl, E. K. 2015, RNA-Based Vaccines in Cancer Immunotherapy, *Journal of Immunology Research*, 1-9.
- Metz, B. 2005, *Structural characterisation of Diphtheria toxoid*, United States.
- Metz, B., Van Dobbelsteen, G. Den, Van Els, C., Van Gun, J. Der, Levels, L., Van Pol, L. Der, Rots, N., & Kersten, G. 2009, Quality-control issues and approaches in vaccine development. *Expert Review of Vaccines*, **8**:227–238.
- Naik, R., & Peden, K. 2020, Regulatory Considerations on the Development of mRNA Vaccines. 1–19.
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. 2018, mRNA vaccines-a new era in vaccinology, *Nature Reviews Drug Discovery*, **17**:261–279.
- Pardi, N., Hogan, M. J., & Weissman, D. 2020, Recent advances in mRNA vaccine technology, *Current Opinion in Immunology*, **65**:14–20.
- Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K. J., Stitz, L., & Kramps, T. 2012, Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection, *Nature Biotechnology*, **30**:1210–1216.
- Plotkin, S. A., & Plotkin, S. L. 2011, The development of vaccines: How the past led to the future, *Nature Reviews Microbiology*, **9**:889–893.
- Ranheim, T., Mozier, N., & Egan, W. 2015, Vaccine potency assays. In *Vaccine Analysis: Strategies, Principles, and Control*.
- Reichmuth, A. M., & Oberli, M. A. 2016, mRNA vaccine delivery using lipid nanoparticles, *Theurapeutic Delivery*, **7**:319–334.
- Salonen, A., Nikkilä, J., Jalanka-Tuovinen, J., Immonen, O., Rajilić-Stojanović, M., Kekkonen, R. A., Palva, A., & de Vos, W. M. 2010, Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: Effective recovery of bacterial and archaeal DNA using mechanical cell lysis, *Journal of Microbiological Methods*, **81**:127–134.

- Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K. J. 2012, Developing mRNA-vaccine technologies. *RNA Biology*, **9**:1319–1330.
- Siegrist, C.-A. 2018, Vaccine Immunology. *Plotkin's Vaccines*, 16-34.
- Travers, A., & Muskhelishvili, G. 2015, DNA structure and function. *FEBS Journal*, **282**:2279–2295.
- Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. 2019, Three decades of messenger RNA vaccine development, Research Gate, **28**:3-45.
- Vetter, V., Denizer, G., Friedland, L. R., Krishnan, J., & Shapiro, M. 2018, Understanding modern-day vaccines: what you need to know. *Annals of Medicine*, **50**:110–120.
- World Health Organization. 2013. Manual for Quality Control of Diphtheria, Tetanus and Pertussis Vaccines. *Immunization, Vaccines and Biologics*, 300.
- World Health Organization. 2020, Evaluation of the quality , safety and efficacy of RNA-based prophylactic vaccines for infectious diseases : regulatory considerations, 1–38.